IQVIA Holdings Inc.
IQV Healthcare Diagnostics & Research
IQVIA Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.3 billion, up 5.87% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS was flat, free cash flow grew 23.3% and total debt rose 3.29%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow IQV
IQVIA Holdings Inc. (IQV) EBITDA
IQVIA Holdings Inc.'s EBITDA for fiscal 2025 was $3.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $3.4B. Over the past ten years it has ranged from $793.0M (fiscal 2015) to $3.3B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 10 consecutive fiscal years. IQVIA Holdings Inc. ranks 3rd of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $3.3B | 0.36% |
| FY2024 | $3.3B | 6.96% |
| FY2023 | $3.1B | 5.98% |
| FY2022 | $2.9B | 10.10% |
| FY2021 | $2.7B | 31.34% |
| FY2020 | $2.0B | 2.21% |
| FY2019 | $2.0B | 5.23% |
| FY2018 | $1.9B | 9.55% |
| FY2017 | $1.7B | 86.61% |
| FY2016 | $926.0M | 16.77% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $804.0M | (0.50%) |
| Mar 2026 | $808.0M | (14.95%) |
| Dec 2025 | $950.0M | 12.43% |
| Sep 2025 | $845.0M | 7.23% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. | $3.4B |
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IQV
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement